USPTO 2015–2025 USPTO PatentsView Foreign Government

Chinese PLA General Hospital

USPTO PatentsView assignee record - 9 granted patents across 11 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

9
Total patents granted
11
CPC technology areas
9.7
Avg claims per patent
+100%
5-year filing velocity

The verdict

Chinese holds 9 US patents across 11 technology areas, rank #28,364 of 50,000 tracked assignees.

#28,364
of 50,000 US assignees by volume
Top 23%
by Innovation Score (45.5/100)
9.7
avg claims per patent
+100%
filing velocity, last 5 yrs

Portfolio overview

Chinese PLA General Hospital has been granted 9 US utility patents between 2015 and 2025, placing Chinese PLA General Hospital at rank #28,364 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Government, Chinese PLA General Hospital is one of the more focused assignees in the PatentsView dataset. By volume, Chinese sits between Cheng YU Enterprises Co., Ltd. (9 patents, rank #28,360) and Chongqing Advance Display Technology Research (9 patents, rank #28,368) - the closest US assignees by grant volume. The composite Innovation Score of 45.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 3 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Government classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Chinese PLA General Hospital's 9.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Chinese PLA General Hospital against peers pursuing similar technology classes.

Who files at Chinese's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Chinese holds 9 patents at rank #28,364, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Chinese

By rank, the assignees closest to #28,364 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Chinese's primary technology class.

Chinese's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

45 Top 23% higher than 77% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201520162022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Chinese PLA General Hospital patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 11.1%
2016 2 22.2%
2022 1 11.1%
2023 3 33.3%
2024 1 11.1%
2025 1 11.1%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating

Where it ranks

Overall rank by patents

#28,364

Across all tracked assignees

Innovation Score

45.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Chinese PLA General Hospital hold?
Chinese PLA General Hospital holds 9 US granted patents filed between 2015 and 2025, spanning 11 technology areas.
What is Chinese PLA General Hospital's Innovation Score?
Chinese PLA General Hospital has an Innovation Score of 45.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Chinese PLA General Hospital focus on?
Chinese PLA General Hospital's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 5 patents. The company has filed patents in 11 CPC subclasses total.
Is Chinese PLA General Hospital's patent filing rate increasing or decreasing?
Chinese PLA General Hospital's recent filing velocity is +100% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Chinese PLA General Hospital's patents?
Chinese PLA General Hospital's patents average 9.7 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Chinese PLA General Hospital patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Chinese's 9 grants land it in the top 23% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Chinese ranks #28,364 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.